Valuation: Amplia Therapeutics Limited

Market Cap 74.43M 51.62M 45.29M 41.79M 38.55M 73.14M 4.93B 500M 196M 2.42B 194M 190M 8.36B P/E 2027 *
-6.3x
P/E 2028 * -24.2x
Enterprise Value 58.93M 40.87M 35.86M 33.09M 30.52M 57.91M 3.9B 396M 155M 1.91B 154M 150M 6.62B EV / Sales 2027 *
-
EV / Sales 2028 * 5.29x
Free-Float
84.81%
Yield 2027 *
-
Yield 2028 * -
1 day+7.41%
1 week-3.33%
1 month+31.82%
3 months-6.45%
6 months-17.14%
Current year-3.33%
1 week 0.14
Extreme 0.135
0.16
1 month 0.1
Extreme 0.105
0.16
Current year 0.1
Extreme 0.1
0.28
1 year 0.1
Extreme 0.1
0.35
3 years 0.05
Extreme 0.049
0.42
5 years 0.05
Extreme 0.049
0.42
10 years 0.04
Extreme 0.045
18.3
Manager TitleAgeSince
Chief Executive Officer - 05/12/2022
Director of Finance/CFO - 01/10/2021
Chief Tech/Sci/R&D Officer - 12/05/2025
Director TitleAgeSince
Director/Board Member 70 02/09/2015
Chairman - 25/05/2018
Chairman - 30/06/2026
Date Insider Type Main position Quantity % Market Cap.
08/09/25Buy

Chairman

152,174 0.0392%
08/09/25Buy

Chairman

336,826 0.0868%
08/09/25Fiscal year

Founder

535,000 0.1379%
Change 5-day change 1-year change 3-year change Capi.($)
+7.41%-3.33%-58.57%+72.62% 51.77M
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average +0.14%-0.58%+41.00%+199.61% 24.16B
Weighted average by Cap. -0.89%-1.45%+51.24%+177.11%

Financials

2027 *2028 *
Net sales - 10M 6.94M 6.09M 5.62M 5.18M 9.83M 662M 67.12M 26.3M 325M 26.07M 25.5M 1.12B
Net income -11.6M -8.04M -7.06M -6.51M -6.01M -11.4M -768M -77.86M -30.51M -377M -30.24M -29.58M -1.3B -3.6M -2.5M -2.19M -2.02M -1.86M -3.54M -238M -24.16M -9.47M -117M -9.38M -9.18M -404M
Net Debt -15.5M -10.75M -9.43M -8.7M -8.03M -15.23M -1.03B -104M -40.76M -504M -40.4M -39.52M -1.74B -21.5M -14.91M -13.08M -12.07M -11.13M -21.13M -1.42B -144M -56.54M -698M -56.04M -54.82M -2.42B
Logo Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. Its pipeline includes narmafotinib (AMP945) and AMP886. Its lead drug candidate, narmafotinib, is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue.
Employees
-
Date Price Change Volume
10/07/26 A$0.1450 +7.41% 727,858
09/07/26 A$0.1350 -3.57% 170,027
08/07/26 A$0.1400 -6.67% 1,263,334
07/07/26 A$0.1500 -3.23% 547,528
06/07/26 A$0.1550 +3.33% 904,101
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1450AUD
Average target price
0.4200AUD
Spread / Average Target
+189.66%

Annual profits - Rate of surprise